IOMX
LIVE

Serial Number

87802718

Owner

IOmx Therapeutics AG

Attorney

Allison R. Imber

Filing Date

Feb 19, 2018

Add to watchlist:

No watchlists yet
View on USPTO

IOMX Trademark

Serial Number: 87802718 • Registration: 6236118

IOMX is a trademark filed by IOmx Therapeutics AG on February 19, 2018. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

IOmx Therapeutics AG (5 trademarks)

Fraunhoferstr. 13

Entity Type: 99

Trademark Details

Filing Date

February 19, 2018

Registration Date

January 5, 2021

Published for Opposition

October 20, 2020

Goods & Services

Scientific services, namely, scientific research, analysis and testing in the fields of biology, chemistry or medicine, as well as in the fields of immunology, oncology, molecular biology, cellular biology, biochemistry and medicinal chemistry; Scientific services, namely, scientific research, analysis and testing in the fields of discovery and development of pharmaceuticals, medical and veterinary preparations, diagnostic preparations and biomarker reagents, and diagnostic apparatus; Design and development of computer software for database management, cloud-storage of data, data-management, data-query, data-analysis and data-presentation, for the query, analysis and presentation of the sequence or structure of molecules, or for predicting or providing a medical diagnosis or prognosis, as well as for controlling and managing patient medical information, with any of the aforementioned services for use in the fields of biology, chemistry or medicine, as well as for use in the fields of immunology, oncology, molecular biology, cellular biology, biochemistry and medicinal chemistry; Design and development of computer software for database management, cloud-storage of data, data-management, data-query, data-analysis and data-presentation, as well as for the query, analysis and presentation of the sequence or structure of molecules, or for predicting or providing a medical diagnosis or prognosis, with any of the aforementioned services for use in the fields of discovery and development of pharmaceuticals, medical and veterinary preparations, diagnostic preparations and biomarker reagents, and diagnostic apparatus

Pharmaceuticals, medical and veterinary preparations, pharmaceutical preparations and formulations, and medicated health preparations, all of the aforesaid goods for use in the treatment or prevention of human and animal diseases, disorders and conditions, namely, circulatory, respiratory, endocrine, neurologic, cardiovascular, alimentary, pulmonary, musculoskeletal, lymphatic or gastrointestinal diseases, disorders and conditions, and for use in the treatment or prevention of complications associated with such diseases, disorders and conditions; Pharmaceuticals, medical and veterinary preparations, pharmaceutical preparations and formulations, and medicated health preparations, all of the aforesaid goods for use in the treatment or prevention of human and animal diseases, disorders and conditions, namely, bone sensory, viral, urinary, renal, metabolic or central nervous system diseases, disorders and conditions, and for use in the treatment or prevention of complications associated with such diseases, disorders and conditions; Pharmaceuticals, medical and veterinary preparations, pharmaceutical preparations and formulations, and medicated health preparations, all of the aforesaid goods for use in the treatment or prevention of human and animal diseases, disorders and conditions, namely, infectious, auto-immune or immune-related, cell-proliferative or oncologic diseases, disorders and conditions, cancers, tumours and metastases, and for use in the treatment or prevention of complications associated with such diseases, disorders and conditions; Diagnostic preparations and biomarker reagents for the diagnosis or prognosis of human and animal diseases, disorders and conditions, namely, circulatory, respiratory, endocrine, neurologic, cardiovascular, alimentary, pulmonary, musculoskeletal, lymphatic or gastrointestinal diseases, disorders and conditions, and for the diagnosis or prognosis of complications associated with such diseases, disorders and conditions; Diagnostic preparations and biomarker reagents for the diagnosis or prognosis of human and animal diseases, disorders and conditions, namely, bone sensory, viral, urinary, renal, metabolic or central nervous system diseases, disorders and conditions, and for the diagnosis or prognosis of complications associated with such diseases, disorders and conditions; Diagnostic preparations and biomarker reagents for the diagnosis or prognosis of human and animal diseases, disorders and conditions, namely, infectious, auto-immune or immune-related, cell-proliferative or oncologic diseases, disorders and conditions, cancers, tumours and metastases, and for the diagnosis or prognosis of complications associated with such diseases, disorders and conditions

Diagnostic apparatus for the diagnosis or prognosis of human and animal diseases, disorders and conditions, namely, circulatory, respiratory, endocrine, neurologic, cardiovascular, alimentary, pulmonary, musculoskeletal, lymphatic or gastrointestinal diseases, disorders and conditions, and for the diagnosis or prognosis of complications associated with such diseases, disorders and conditions, specifically, sample-analysis devices and related data-analysis software sold as a unit, nucleic acid-analysis or protein-analysis diagnosis apparatus, and diagnostic apparatus utilizing a diagnostic or prognosis algorithm and related algorithm software sold as a unit; Diagnostic apparatus for the diagnosis or prognosis of human and animal diseases, disorders and conditions, namely, bone sensory, viral, urinary, renal, metabolic or central nervous system diseases disorders and conditions, and for the diagnosis or prognosis of complications associated with such diseases, disorders and conditions, specifically, sample-analysis devices and related data-analysis software sold as a unit, nucleic acid-analysis or protein-analysis diagnosis apparatus, and diagnostic apparatus utilizing a diagnostic or prognosis algorithm and related algorithm software sold as a unit; Diagnostic apparatus for the diagnosis or prognosis of human and animal diseases, disorders and conditions, namely, infectious, auto-immune or immune-related, cell-proliferative or oncologic diseases, disorders and conditions, cancers, tumours and metastases, and for the diagnosis or prognosis of complications associated with such diseases, disorders and conditions, specifically, sample-analysis devices and related data-analysis software sold as a unit, nucleic acid-analysis or protein-analysis diagnosis apparatus, and diagnostic apparatus utilizing a diagnostic or prognosis algorithm and related algorithm software sold as a unit

Filing History

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Jan 5, 2026 REM1
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 8, 2024 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Feb 8, 2024 ECDR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
Feb 8, 2024 EWOR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 8, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 8, 2024 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Feb 8, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Feb 8, 2024 COAR
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Mar 6, 2023 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 6, 2023 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Mar 6, 2023 ECDR
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Mar 6, 2023 EWAF
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 6, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 6, 2023 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Mar 6, 2023 COAR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 8, 2021 TCCA
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
Oct 8, 2021 EWOR
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Oct 8, 2021 EWAF
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 8, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 8, 2021 REAP
REGISTERED-PRINCIPAL REGISTER
Jan 5, 2021 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 20, 2020 NPUB
PUBLISHED FOR OPPOSITION
Oct 20, 2020 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 30, 2020 NONP
ELECTRONIC RECORD REVIEW COMPLETE
Sep 15, 2020 FIXD
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Sep 11, 2020 ERRR
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 10, 2020 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 25, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 24, 2020 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Aug 24, 2020 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Jul 9, 2020 GNFN
FINAL REFUSAL E-MAILED
Jul 9, 2020 GNFR
FINAL REFUSAL WRITTEN
Jul 9, 2020 CNFR
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Jun 24, 2020 RCCK
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Dec 18, 2019 RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Jun 18, 2019 RCSC
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Dec 12, 2018 GNS3
LETTER OF SUSPENSION E-MAILED
Dec 12, 2018 GNSL
SUSPENSION LETTER WRITTEN
Dec 12, 2018 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 10, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 10, 2018 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 3, 2018 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 4, 2018 GNRN
NON-FINAL ACTION E-MAILED
Jun 4, 2018 GNRT
NON-FINAL ACTION WRITTEN
Jun 4, 2018 CNRT
ASSIGNED TO EXAMINER
Jun 4, 2018 DOCK
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Apr 3, 2018 AMPX
ASSIGNED TO LIE
Mar 30, 2018 ALIE
TEAS VOLUNTARY AMENDMENT RECEIVED
Mar 16, 2018 PARI
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 26, 2018 NWOS
NEW APPLICATION ENTERED
Feb 22, 2018 NWAP